Palvella Therapeutics (NASDAQ:PVLA) Stock Jumps 6.4% - Here's Why

Key Points

• Palvella Therapeutics shares rose 6.4% to about $141.36 in midday trading, although volume was 82% below the stock’s average daily level.
• Analysts remain broadly optimistic, with a consensus “Moderate Buy” rating and an average price target of $209.79; targets from several firms range from $207 to $232.
• The company reported a larger-than-expected quarterly loss of $1.52 per share versus the $1.17 consensus estimate, while insiders sold approximately $8.76 million of stock over the past 90 days.

Palvella Therapeutics, Inc. (NASDAQ:PVLA - Get Free Report)'s stock price shot up 6.4% during mid-day trading on Wednesday. The company traded as high as $140.21 and last traded at $141.3590. 45,383 shares traded hands during trading, a decline of 82% from the average daily volume of 257,533 shares. The stock had previously closed at $132.91.

Wall Street Analysts Forecast Growth

Several research firms recently commented on PVLA. Raymond James Financial set a $226.00 target price on Palvella Therapeutics in a research report on Friday, October 16th. Canaccord Genuity Group set a $232.00 price target on Palvella Therapeutics in a research note on Wednesday, August 5th. William Blair assumed coverage on Palvella Therapeutics in a report on Friday, October 16th. They set an "outperform" rating on the stock. Truist Financial set a $207.00 price objective on shares of Palvella Therapeutics in a research note on Wednesday, August 5th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Palvella Therapeutics in a research note on Friday, September 25th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, Palvella Therapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $209.79.

Palvella Therapeutics Stock Performance

The firm has a 50 day moving average price of $141.42 and a 200-day moving average price of $125.93. The company has a market cap of $2.04 billion, a P/E ratio of -29.53 and a beta of -0.27.

Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($1.52) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.35). On average, sell-side analysts forecast that Palvella Therapeutics, Inc. will post -6.41 EPS for the current fiscal year.

Insider Activity at Palvella Therapeutics

In other news, COO Kathleen Goin sold 4,313 shares of the firm's stock in a transaction dated Wednesday, October 21st. The shares were sold at an average price of $124.58, for a total value of $537,313.54. Following the transaction, the chief operating officer owned 2,165 shares of the company's stock, valued at approximately $269,715.70. This trade represents a 66.58% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Christopher P. Kiritsy sold 313 shares of the business's stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $157.00, for a total transaction of $49,141.00. Following the sale, the director directly owned 250 shares of the company's stock, valued at approximately $39,250. This trade represents a 55.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 61,056 shares of company stock valued at $8,756,946 over the last ninety days. 17.20% of the stock is owned by insiders.

Institutional Investors Weigh In On Palvella Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PVLA. China Universal Asset Management Co. Ltd. grew its position in shares of Palvella Therapeutics by 31.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,783 shares of the company's stock worth $248,000 after buying an additional 426 shares during the period. Sterling Capital Management LLC grew its holdings in shares of Palvella Therapeutics by 907.7% in the 3rd quarter. Sterling Capital Management LLC now owns 393 shares of the company's stock valued at $54,000 after buying an additional 354 shares during the period. Avior Wealth Management LLC bought a new stake in shares of Palvella Therapeutics in the 3rd quarter valued at $212,000. Arizona State Retirement System increased its position in shares of Palvella Therapeutics by 30.9% in the 2nd quarter. Arizona State Retirement System now owns 2,765 shares of the company's stock valued at $423,000 after buying an additional 652 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. acquired a new stake in Palvella Therapeutics during the 2nd quarter worth $35,000. Institutional investors own 40.11% of the company's stock.

About Palvella Therapeutics

Palvella Therapeutics, Inc NASDAQ: PVLA is a clinical-stage biopharmaceutical company focused on developing treatments for patients with serious rare diseases, including conditions that may have limited or no approved therapeutic options.

The company's development programs are based on its QTORIN 3.0 technology platform, which is designed to deliver medicines locally through topical formulations. Palvella has applied the platform to investigational therapies for rare genetic skin disorders and other localized diseases, with the goal of improving treatment effectiveness while limiting systemic exposure.

Palvella is headquartered in Wayne, Pennsylvania, and conducts research and development activities aimed at serving rare-disease patients in the United States and other potential international markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.